ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on targeting CD123-positive leukemic cells with its DART®-based molecule, MGD006, will be featured in an oral presentation at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans on December 7-10, 2013.
The details of the presentation are as follows:
|Session:||615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Antibody-Based Targeted Therapy|
|Date:||December 9, 2013|
|Time:||11:45 am CST (oral presentation)|
|Location:||La Nouvelle Ballroom C (Ernest N. Morial Convention Center)|
|Title:||Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs)|
|Presenter:||Muneera H. Al-Hussaini, M.D., an investigator from the Division of Hematology & Oncology, Washington University School of Medicine in St. Louis|
|Description:||The team investigated the ability of a DART constructed from an antibody to CD123 (7G3) and a MacroGenics' proprietary CD3 antibody, MGD006, to redirect T cells against CD123+ AML blasts.|
MacroGenics is developing MGD006 for the treatment of hematologic cancers. MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. The primary mechanism of action of MGD006 is its ability to redirect T cells via their CD3 component to kill CD123-expressing cells, as shown in pre-clinical studies. This product candidate is poised to enter the clinic in the first half of 2014.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. www.macrogenics.com
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
CONTACT: Jim Karrels, Vice President, CFO MacroGenics, Inc. 1-301-251-5172, firstname.lastname@example.org Karen Sharma, Director MacDougall Biomedical Communications 1-781-235-3060, email@example.com
|MacroGenics Announces Presentation of Pre-Clinical Data on DART(R) Molecule Targeting CD123-Positive Leukemic Stem Cells at 55th Annual Meeting of the American Society of Hematology (2013/12/9)|
|MacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting (2014/3/31)|
|Epizyme, Inc. to Present Pre-Clinical Data on DOT1L and EZH2 Inhibitor Programs at the 55th ASH Annual Meeting (2013/11/7)|
|MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting (2014/4/6)|
|ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 55th ASH Annual Meeting and Exposition (2013/12/3)|
|Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting ()|
|Karyopharm Therapeutics Announces Highlights From Poster Presentations on Selective Inhibitors of Nuclear Export (SINE) Compounds in Hematologic Malignancies at 2013 ASH Annual Meeting (2013/12/7)|
|OncoMed Pharmaceuticals to Present Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (anti-CSC) Therapeutics in Five Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013 (2013/10/14)|
|Alnylam to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology (ASH) ()|
|Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa (PRT4445*) and PRT2070 at 55th American Society of Hematology (ASH) Annual Meeting (2013/12/3)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.